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group and 64.7% (11/17) in the CS group. 18 patients had disease
progression (NCS 10, CS 8); median TTP was 5.5 months in the
NCS group and 3 months in the CS group, and average TTP was
5.3 months in NCS group and 3.1 months in CS group. The inci-
dence of adverse events was similar for both groups. No adverse
events of grade 3 skin rash or grade 3 infusion-related reactions
were observed.
Interpretation: This study provides evidence that nimotuzumab
combined with cisplatin and S-1 has better outcomes than cis-
platin and S-1. Initial results show a benefit in TTP improvement
and a potential improvement in OS, and the study is ongoing.
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Background: Recent surgical trials show that in patients with
rectal carcinoma, evaluating the involvement of the mesorectal
fat and mesorectal fascia is more important than T staging for
planning treatment. We studied the accuracy of 3T MRI for predic-
tion of mesorectal fascia involvement and circumferential resec-
tion margin (CRM; shortest distance between tumour and
mesorectal fascia) in patients with rectal cancer.
Methods: 40 consecutive patients with biopsy-proven rectal
cancer from the Department of Colorectal Surgery were included
in the study. 3T MR imaging was done after patients had a 4-h fast
and cleansing water enema. T1-weighted and T2-weighted
images were obtained, with high resolution images in 3 planes.
The image series were evaluated after verification by an experi-
enced gastrointestinal radiologist, and CRM measurements and
mesorectal fascia involvement were documented. These results
were compared with the final histopathology report.
Findings: Sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) of 3T MRI for prediction of
CRM involvement was 100%, 33.3%, 61.9%, and 100%, respectively.
Interpretation: 3T MRI has high sensitivity and NPV, and low
specificity and PPV for prediction of CRM involvement. The low
specificity could be due to the high resolution of the images,
which picked up areas of tumour reaction, increased flow, and
oedema. This low specificity is compounded by the difficulty in
assessing CRM in cachectic patients and in low anterior tumours.
However, MR imaging has a high sensitivity and NPV for mesorec-
tal fascia assessment, and is therefore indispensable for pre-oper-
ative staging of rectal cancer.
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Background: Gamboge Acid is a pure active compound isolated
from the Camboge (Garcinia morella Desv), a traditional Chinese
herb medicine. Based on preliminary results of the completed
phase 1 study, this phase 2a study compared the efficacy and
safety of different dosage schedules.
Methods: 47 patients were randomly assigned to one of two
groups. Group A received a daily intravenous infusion of gam-
boge acid (THS) of 45 mg/m2 every day for 5 days, every 2 weeks
(n = 21). Group B received intravenous THS 45 mg/m2 every other
day five times, every 2 weeks (n = 26). All patients had two con-
secutive courses of treatment prior to safety and efficacy
evaluation.
Findings: In group A, the objective remission rate (ORR) was
14.29% and overall disease control rate (DCR) was 76.2%, com-
pared with an ORR of 0% and DCR of 61.5% in group B. Apart from
ORR (with a insufficient value of zero) comparison of DCR was
statistically significant (p = 0.0456), with a positive relative risk
and odds ratio and 95% confidence intervals. Adverse events or
reactions were mainly grade 1 and 2, and were observed, in most
cases, after patients received the trial drugs. The incidence rate of
adverse events or reactions did not differ significantly between
the two groups.
Interpretation: Preliminary results of this exploratory study
showed favourable safety profiles for THS at 45 mg/m2, and DCR
was higher for 5-day consecutive dosing of THS than for an
every-other-day schedule.
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